Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan ) in Recurrent Glioblastoma

  • End date
    Apr 27, 2026
  • participants needed
  • sponsor
    University Hospital Muenster
Updated on 27 April 2021
Juliane Schroeteler, Dr. med.
Primary Contact
Medizinische Fakult t Carl Gustav Carus, Klinik und Poliklinik f r Neurochirurgie (7.4 mi away) Contact
+4 other location


In this multicenter, randomized, non-blinded trial the efficacy and safety of stereotactical photodynamic therapy with 5-aminolevulinic acid will be investigated in 106 patients with recurrent glioblastoma.

Condition Glioblastoma Multiforme, Adult, Glioblastoma Multiforme, Adult, Glioblastoma Multiforme, Adult, Glioblastoma Multiforme, Adult
Treatment Stereotactic biopsy, Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid
Clinical Study IdentifierNCT04469699
SponsorUniversity Hospital Muenster
Last Modified on27 April 2021


Yes No Not Sure

Inclusion Criteria

Written informed consent
Age 18 - 75 years
Karnofsky Performance Score (KPS) of 60 %
Radiologically suspected diagnosis (according to RANO criteria) of the first recurrence of a glioblastoma located in the cerebral hemisphere including insular and diencephalon. Tumors in the brain stem are excluded. First MRI with signs of first recurrence (radiologic RANO criteria for disease progression) within 8 weeks prior to Informed Consent. Not necessarily identical to primary tumor location
Single or single progressive contrast-enhancing lesion on MRI, largest diameter not more than 2.5 cm
For female and male patients of reproductive potential: Willingness to apply highly effective contraception (Pearl index <1) during the entire study

Exclusion Criteria

Multifocal disease > 2 locations
Patients with significant non-enhancing tumor portions
Previous treatment of recurrence
Other malignant disease except basalioma
Hypersensitivity against porphyrins or Gliolan or Fluorethylenpropylen (FEP )
HIV infection, active Hepatitis B or C infection
Bone marrow reserve
white blood cell (WBC) count <2000/l
platelets <100000/l
Liver function
total bilirubin > 1.5 times above upper limit of normal range (ULN)
alanine transaminase (ALT) and aspartate transaminase (AST) > 3 times ULN
Renal function
creatinine > 1.5 times ULN
Blood clotting
Quick/INR or PTT out of acceptable limits
Conditions precluding MRI (e.g. pacemaker)
Past medical history of diseases with poor prognosis, e.g. severe coronary heart disease, heart failure (NYHA III/IV), severe poorly controlled diabetes, immune deficiency, residual deficits after stroke, severe mental retardation or other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)
Any active infection (at the discretion of the investigator)
Any psychological, cognitive, familial, sociological or geographical condition that, in the investigator's opinion, compromises the patient's ability to understand the patient information, to give informed consent or to comply with the trial protocol
Previous antiangiogenic treatment
Participation in another interventional clinical trial during this trial or within 4 weeks before entry into this trial
Pregnancy or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note